Atopic dermatitis affects approximately 200 million people worldwide, including about 26 million individuals in the United States. Despite its prevalence, current treatment options often rely on injectables, which can present barriers related to cost, accessibility, and patient adherence, or oral therapies that carry significant safety concerns, including black box warnings of potential organ toxicity and systemic side effects.